Jiangsu CoWin Biotech Co., Ltd. (SHA:688426)
China · Delayed Price · Currency is CNY 21.23
-0.70 (-3.19%)
At close: May 12, 2026
Jiangsu CoWin Biotech Cash Flow Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Net Income | -103.94 | -111.33 | -157.21 | -84.41 | 159.26 | 125.85 |
Depreciation & Amortization | 34.57 | 34.57 | 38.83 | 33.55 | 23.25 | 15.73 |
Other Amortization | 3.06 | 3.06 | 4.33 | 3.69 | 3.06 | 2.31 |
Loss (Gain) From Sale of Assets | -0.24 | -0.24 | -0.19 | -1.24 | 0.51 | -1.29 |
Asset Writedown & Restructuring Costs | -1.95 | -1.95 | 3.44 | 4.27 | 0.06 | 0.03 |
Loss (Gain) From Sale of Investments | -13.77 | -13.77 | -18.21 | -26.71 | -7.94 | -7.57 |
Provision & Write-off of Bad Debts | - | - | 21.67 | 20.8 | 9.51 | 1.6 |
Other Operating Activities | -22.97 | 0.09 | 3.83 | 8.94 | 16.85 | 3.13 |
Change in Accounts Receivable | -14.6 | -14.6 | -11.84 | 52.74 | -97.15 | -16.08 |
Change in Inventory | -4.97 | -4.97 | -19.48 | 17.55 | -23.29 | -9.6 |
Change in Accounts Payable | 44.43 | 44.43 | 21.91 | -43.75 | 14.18 | 20.47 |
Change in Other Net Operating Assets | 0.94 | 0.94 | 2.9 | 16.33 | 13.15 | 8.43 |
Operating Cash Flow | -74.66 | -58.99 | -113.26 | -11.72 | 107.37 | 144.5 |
Operating Cash Flow Growth | - | - | - | - | -25.70% | 32.70% |
Capital Expenditures | -24.83 | -34.82 | -48.41 | -159.22 | -100.38 | -124.39 |
Sale of Property, Plant & Equipment | 0.54 | 0.54 | 0.2 | 1.01 | 0.01 | 0.08 |
Cash Acquisitions | - | - | -13.83 | - | -5.21 | - |
Investment in Securities | 183.35 | 20.33 | 121.31 | -479 | -165 | 68.6 |
Other Investing Activities | 40.58 | 17.53 | 14.89 | 16.29 | 6.77 | 8.71 |
Investing Cash Flow | 199.64 | 3.58 | 74.16 | -620.91 | -263.81 | -47 |
Long-Term Debt Issued | - | 4 | 6 | - | - | - |
Long-Term Debt Repaid | - | -6 | -14.4 | -7.57 | -5.31 | -4.54 |
Net Debt Issued (Repaid) | -10 | -2 | -8.4 | -7.57 | -5.31 | -4.54 |
Issuance of Common Stock | - | - | 3.06 | - | 1,083 | - |
Repurchase of Common Stock | - | - | -43.66 | - | - | - |
Common Dividends Paid | -0.25 | -0.26 | -3.9 | -50.73 | - | - |
Other Financing Activities | -29.14 | -35.63 | - | 6 | -19.27 | -3.22 |
Financing Cash Flow | -39.39 | -37.88 | -52.9 | -52.3 | 1,058 | -7.76 |
Foreign Exchange Rate Adjustments | -1.52 | -0.89 | 0.21 | 0.64 | 1.79 | -0.77 |
Net Cash Flow | 84.07 | -94.19 | -91.79 | -684.29 | 903.72 | 88.98 |
Free Cash Flow | -99.49 | -93.82 | -161.67 | -170.94 | 6.99 | 20.11 |
Free Cash Flow Growth | - | - | - | - | -65.25% | -78.93% |
Free Cash Flow Margin | -47.49% | -48.48% | -128.44% | -99.77% | 1.34% | 5.94% |
Free Cash Flow Per Share | -0.90 | -0.85 | -1.45 | -1.52 | 0.07 | 0.24 |
Cash Income Tax Paid | 1.38 | 2.1 | 5.66 | 23.45 | 36.72 | 17.62 |
Levered Free Cash Flow | -69.76 | -425.79 | -127.04 | -115.19 | -38.17 | -9.99 |
Unlevered Free Cash Flow | -69.76 | -425.79 | -126.16 | -114.13 | -36.96 | -8.79 |
Change in Working Capital | 30.58 | 30.58 | -9.75 | 29.39 | -97.19 | 4.71 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.